Amendments To The Claims

1-6. (canceled)

7. (currently amended) A~~The~~ compound selected from the following ~~represented by~~ formulae (C1) to (C11) and (C13)-(C20)~~C(1) to (C39)~~ or a pharmaceutically acceptable salt or prodrug derivative thereof:

C1)



,

C2)



,

C3)



,

C4)



,

C5)



,

C6)



,

C7)



,

C8)



C9)



,

C10)



,

C11)



,

C13)



,

C14)



,

C-15)



,

C16)



,

C17)



,

C18)



C19)



C20)



~~C21)~~



~~C22)~~



~~C23~~



~~C24~~



~~C25)~~



~~C26)~~



~~C27)~~



~~C28)~~



~~C29)~~



~~C30)~~



~~C31)~~



~~C32)~~



~~C33)~~



~~C34)~~



~~C35)~~



~~;~~

~~C36)~~



~~;~~

~~C37)~~



~~;~~

~~C38)~~



~~; or~~

~~C39)~~



.

8. (currently amended) A~~The~~ compound represented by the structural formula AA



(AA)

or a pharmaceutically acceptable salt or prodrug thereof.

9. (currently amended) A compound selected from the group consisting of:







,



,



,



,


O
O
O
N
OH
O
O
,


O
O
O
N
OH
O
O
,


OH
O
O
O
OH
,


O
O
OH
O
O
S
O
O
,


O
O
O
O
S
O
O
,


O
O
O
O
OH
O
,


O
O
O
O
OH
OH
,


O
O
OH
O
HO

,


O
OH
O
O
OH

,


O
O
O
H
N
O
O
OH

,


O
O
O
N
O
O
OH

,


O
O
O
N
O
O
OH

,



,



,



,





,



,



,



,



,

or a pharmaceutically acceptable salt or prodrug derivative thereof.

10. (canceled)

11. (currently amended) ~~The prodrug~~ An ester derivative of the compound of claim 36~~1 wherein the prodrug is~~selected from a methyl ester; ethyl ester; N,N-diethylglycolamido ester; or morpholinylethyl ester.

12. (currently amended) The salt derivative of the compound of claim 36~~1~~ wherein the salt is sodium or potassium.

13. (currently amended) A pharmaceutical formulation comprising the compound of claim 36~~1~~ either with a pharmaceutically acceptable carrier or diluent.

14. (withdrawn, currently amended) A formulation for treating osteoporosis comprising:

Ingredient (A1): the vitamin D receptor modulator of claim 36~~1~~ or;

Ingredient (B1):

one or more co-agents selected from the group consisting of:

a. estrogens,

b. androgens,

c. calcium supplements,

d. vitamin D metabolites,

e. thiazide diuretics,

f. calcitonin,

g. bisphosphonates,

h. SERMS, and

i. fluorides; and

Ingredient (C1): optionally, a carrier or diluent.

15. (withdrawn) The formulation of claim 14 wherein the weight ratio of (A1) to (B1) is from 10:1 to 1:1000.

16. (withdrawn, currently amended) A formulation for treating psoriais comprising:

Ingredient (A2): the vitamin D receptor modulator of claim 36~~1~~;

Ingredient (B2):

one or more co-agents that are conventional for treatment psoriasis selected from the group consisting of:

a. topical glucocorticoids ,

b. salicylic acid,

c. crude coal tar; and

Ingredient (C2): optionally, a carrier or diluent.

17. (withdrawn) The formulation of claim 16 wherein the weight ratio of (A2) to (B2) is from 1:10 to 1:100000.

18. (withdrawn, currently amended) A method of treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, ~~Alopecia , Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia , Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome,~~ Insufficient sebum secretion, ~~Osteomalacia,~~ Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, ~~Psoriatic arthritis, Prostate cancer,~~ Psoriasis, ~~Renal osteodystrophy, Rheumatoid arthritis,~~ Scleroderma, Skin cancer, ~~Systemic lupus erythematosus,~~ Skin cell damage from, Mustard vesicants, ~~Ulcerative colitis, Vitiligo, or~~ Wrinkles or Seborrheic dermatitis; wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to claim 36~~1~~.

19. (withdrawn) The method of claim 18 for the treatment of psoriasis.

20. (withdrawn) The method of claim 18 for the treatment of osteoporosis.

21-22. (canceled)

23. (withdrawn, currently amended) A method of treating or preventing disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound according to claim 36~~1~~.

24-35. (canceled)

36. (new) A compound represented by a formula below:



wherein

R and R' are independently C_1-C_5 alkyl, C_1-C_5 fluoroalkyl, or together R and R' form a substituted or unsubstituted, saturated or unsaturated carbocyclic ring having from 3 to 8 carbon atoms;

RP_3 is selected from hydrogen, halo, C_1-C_5 alkyl, C_1-C_5 fluoroalkyl, -O-C_1-C_5 alkyl, -S-C_1-C_5 alkyl, -O-C_1-C_5 fluoroalkyl, -CN, -NO_2, acetyl, -S-C_1-C_5 fluoroalkyl, C_2-C_5 alkenyl, C_3-C_5 cycloalkyl, or C_3-C_5 cycloalkenyl;

(L_{P2}) is a divalent linking group independently selected from:

a bond ,



,

,



,



,



,



, and

,

where m is 0, 1, or 2, and each R40 is independently hydrogen, C_1-C_5 alkyl, or C_1-C_5 fluoroalkyl;

Z_P is

branched C_3-C_5 alkyl,

1-hydroxycyclopentenyl,

1-hydroxycyclohexenyl,

1-hydroxycycloheptenyl,

1-hydroxycyclooctenyl,

1-hydroxycyclopropyl,

1-hydroxycyclobutyl,

1-hydroxycyclopentyl,

1-hydroxycyclohexyl,

2-oxocyclohexyloxy

2-oxocyclohexylmethyl

3-methyl-2-oxocyclohexyloxy

3-methyl-2-oxocyclohexylmethyl

3,3-dimethyl-2-oxocyclohexyloxy

3,3-dimethyl-2-oxocyclohexylmethyl

2-hydroxycyclohexyloxy

2-hydroxycyclohexylmethyl

3-methyl-2-hydroxycyclohexyloxy

3-methyl-2-hydroxycyclohexylmethyl

3,3-dimethyl-2-hydroxycyclohexyloxy

3,3-dimethyl-2-hydroxycyclohexylmethyl

1-hydroxycycloheptyl, or

1-hydroxycyclooctyl;

Z_{FB} is attached to the 5 or 6 position on the benzofuranyl ring and selected from:

$-CO_2H$

$-CO_2(C_1\text{-}C_5$ alkyl),

$-CO_2(C_2\text{-}C_5$ alkenyl),

$-CO_2(C_3\text{-}C_5$ cycloalkyl),

$-CO_2(C_3\text{-}C_5$ cycloalkenyl),

$-CO_2(C_1\text{-}C_5$ hydroxyalkyl),

$-CO_2(C_1\text{-}C_5$ fluoroalkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-phenyl,

$-CO_2(C_1\text{-}C_5$ alkyl)-(O)-($C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-NH_2,

$-CO_2(C_1\text{-}C_5$ alkyl)-NH-($C_1\text{-}C_5$ alkyl)$_2$,

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-NH_2,

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-NH-($C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-N-($C_1\text{-}C_5$ alkyl)$_2$,

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-OH,

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-NH-5-tetrazolyl,

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-($C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-C(O)-(O-$C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-NH_2,

$-CO_2(C_1\text{-}C_5$ alkyl)-NH-($C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-N-($C_1\text{-}C_5$ alkyl)$_2$,

$-CO_2(C_1\text{-}C_5$ alkyl)-NH-SO_2-($C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-N-pyrrolidin-2-one,

$-CO_2(C_1\text{-}C_5$ alkyl)-N-pyrrolidine,

$-CO_2(C_1\text{-}C_5$ alkyl)-(1-methylpyrrolidin-2-one-3-yl),

$-CO_2(C_1\text{-}C_5$ alkyl)-SO_2-($C_1\text{-}C_5$ alkyl,)

$-CO_2(C_1\text{-}C_5$ alkyl)-SO_2-NH_2,

$-CO_2(C_1\text{-}C_5$ alkyl)-SO_2-NH-($C_1\text{-}C_5$ alkyl),

$-CO_2(C_1\text{-}C_5$ alkyl)-SO_2-N-($C_1\text{-}C_5$ alkyl)$_2$,

-$CO_2(C_1\text{-}C_5$ alkyl)-SO_2-($C_1\text{-}C_5$ alkyl),

-$CO_2(C_1\text{-}C_5$ alkyl)-S(O)-($C_1\text{-}C_5$ alkyl,)

- $CO_2(C_1\text{-}C_5$ alkyl)-S(O)-NH_2,

-$CO_2(C_1\text{-}C_5$ alkyl)-S(O)-NH-($C_1\text{-}C_5$ alkyl),

-$CO_2(C_1\text{-}C_5$ alkyl)-S(O)-N-($C_1\text{-}C_5$ alkyl)$_2$,

-$CO_2(C_1\text{-}C_5$ alkyl)-S(O)-($C_1\text{-}C_5$ alkyl),

-$CO_2(C_1\text{-}C_5$ alkyl)-P(O)-(O-$C_1\text{-}C_5$ alkyl)$_2$,

-$CO_2(C_1\text{-}C_5$ alkyl)-5-tetrazolyl,

-CO_2CH_2-CO_2H,

-CO_2CH_2-5-tetrazolyl,

-$CO_2(C_1\text{-}C_5$ alkyl),

-CO_2C(O)-NH_2,

-CO_2C(O)-N-$(CH_3)_2$,

-CO_2C(S)-N-$(CH_3)_2$,

-CO_2C(O)-O-($C_1\text{-}C_5$ alkyl),

-CO_2(5-tetrazolyl),

-CO_2SO_2-($C_1\text{-}C_5$ alkyl,)

-CO_2SO_2-NH_2,

-CO_2SO_2-NH-($C_1\text{-}C_5$ alkyl),

-CO_2SO_2-N-($C_1\text{-}C_5$ alkyl)$_2$,

-CO_2S(O)-($C_1\text{-}C_5$ alkyl,)

-CO_2S(O)-NH_2,

-CO_2S(O)-NH-($C_1\text{-}C_5$ alkyl),

-CO_2S(O)-N-($C_1\text{-}C_5$ alkyl)$_2$,

-C(O)NH-CH_2-C(O)OH,

-C(O)NH-CH_2-C(O)OMe,

-C(O)NH-CH_2-C(O)OEt,

-C(O)NH-CH_2-C(O)OiPr,

-C(O)NH-CH_2-C(O)OtBu,

-C(O)NH-CH(Me)-C(O)OH,

-C(O)NH-CH(Me)-C(O)OMe,

-C(O)NH-CH(Me)-C(O)OEt,

-C(O)NH-CH(Me)-C(O)iPr,

-C(O)NH-CH(Me)-C(O)tBu,

-C(O)NH-CH(Et)-C(O)OH,

-C(O)NH-$C(Me)_2$-C(O)OH,

-C(O)NH-$C(Me)_2$-C(O)OMe,

-C(O)NH-$C(Me)_2$-C(O)OEt,

-C(O)NH-$C(Me)_2$-C(O)iPr,

-C(O)NH-$C(Me)_2$-C(O)tBu,

-C(O)NH-CMe(Et)-C(O)OH,

-C(O)NH-CH(F)-C(O)OH,

-C(O)NH-$CH(CF_3)$-C(O)OH,

-C(O)NH-CH(OH)-C(O)OH,

-C(O)NH-CH(cyclopropyl)-C(O)OH,

-C(O)NH-$C(Me)_2$-C(O)OH,

-C(O)NH-$C(Me)_2$-C(O)OH,

-C(O)NH-CF(Me)-C(O)OH,

-C(O)NH-C(Me)(CF_3)-C(O)OH,

-C(O)NH-C(Me)(OH)-C(O)OH,

-C(O)NH-C(Me)(cyclopropyl)CO_2H

-C(O)NMe-CH_2-C(O)OH,

-C(O)NMe-CH_2-C(O)OMe,

-C(O)NMe-CH_2-C(O)OEt,

-C(O)NMe-CH_2-C(O)OiPr,

-C(O)NMe-CH_2-C(O)tBu,

-C(O)NMe-CH_2-C(O)OH,

-C(O)NMe-CH(Me)-C(O)OH,

-C(O)NMe-CH(F)-C(O)OH,

-C(O)NMe-$CH(CF_3)$-C(O)OH,

-C(O)NMe-CH(OH)-C(O)OH,

-C(O)NMe-CH(cyclopropyl)-C(O)OH,

-C(O)NMe-$C(Me)_2$-C(O)OH,

-C(O)NMe-CF(Me)-C(O)OH,

-C(O)NMe-C(Me)(CF_3)-C(O)OH,

-C(O)NMe-C(Me)(OH)-C(O)OH,

-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH,

-C(O)NHS(O)Me,

-C(O)$NHSO_2$Me,

-C(O)-NH-5-tetrazolyl,

-C(O)NHS(O)Me,

-C(O)NHS(O)Et,

-C(O)$NHSO_2$Me,

-C(O)$NHSO_2$Et,

-C(O)NHS(O)iPr,

-C(O)$NHSO_2$iPr,

-C(O)NHS(O)tBu,

-C(O)$NHSO_2$tBu,

-C(O)$NHCH_2$S(O)Me,

-C(O)$NHCH_2$S(O)Et,

-C(O)$NHCH_2SO_2$Me,

-C(O)$NHCH_2SO_2$Et,

-C(O)$NHCH_2CH_2$S(O)Me,

-C(O)$NHCH_2CH_2$S(O)Et,

-C(O)$NHCH_2CH_2SO_2$Me,

-C(O)$NHCH_2CH_2SO_2$Et,

-C(O)N(Me)S(O)Me,

-C(O)N(Me)SO_2Me,

-C(O)-N(Me)-5-tetrazolyl,

-C(O)N(Me)S(O)Me,

-C(O)N(Me)S(O)Et,

-C(O)N(Me)SO_2Me,

-C(O)N(Me)SO_2Et,

-C(O)N(Me)S(O)iPr,

-C(O)N(Me))SO_2iPr,

-C(O)N(Me))S(O)tBu,

-C(O)N(Me)SO_2tBu,

-C(O)N(Me)$CH_2S(O)Me$,

-C(O)N(Me)$CH_2S(O)Et$,

-C(O)N(Me)CH_2SO_2Me,

-C(O)N(Me)CH_2SO_2Et,

-C(O)N(Me)$CH_2CH_2S(O)Me$,

-C(O)N(Me)$CH_2CH_2S(O)Et$,

-C(O)N(Me)$CH_2CH_2SO_2Me$, and

-C(O)N(Me)$CH_2CH_2SO_2Et$;

and a pharmaceutically acceptable salt or prodrug thereof.

37. (new) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

38. (new) A compound represented by a formula:



,

and pharmaceutically acceptable salts thereof.

39. (new) A method of treating a mammal or alleviating the pathological effects of psoriasis, scleroderma, seborrheic dermatitis or skin cancer or, a mammal in need thereof comprising administered a pharmaceutically effective amount of a compound of Claim 37, or a pharmaceutically acceptable salt thereof.